$AMN

AMN Healthcare Services' stock has surged 118.7% year-to-date, outperforming its industry and the S&P 500. Q2 revenues rose 2.3% to $673M, exceeding guidance, with adjusted EPS up 158% YoY. Growth is driven by strong demand in nurse and allied staffing, technology enhancements, and persistent healthcare workforce shortages. The company's 2026 EPS is projected to grow 127.9% to $3.10, with revenues expected to rise 20.9% to $3.30B.

AMN Healthcare Services reported Q2 2026 sales of $673.24M and returned to profitability. The company also joined the AONL Foundation Corporate Advisory Council. Analysts debate whether earnings momentum and raised guidance will sustain revenue stability amid margin pressures and tighter hospital budgets. AMN projects $2.4B revenue and $2.5M earnings by 2029, but some analysts expect a 9% revenue decline annually.

AMN Healthcare reported Q2 2026 language services revenue of $69.6m, down 8% YoY due to pricing pressure. Overall revenue rose 2% to $673.2m, with net income at $21.2m. The company acquired Jaide Health for AI interpreting services and expects Q3 revenue of $640m-$655m.

A Q2 earnings wrap for 39 healthcare providers and services stocks says group revenues beat analysts’ consensus by 1.7% and next-quarter guidance was 1.6% above. It highlights AMN Healthcare Services (AMN) revenue of $673.2M (+2.3% YoY), beating estimates by 7.2%, and stock up 11.7% to $34.41. Other featured names include CVS, AdaptHealth, McKesson, and Encompass Health.

AMN Healthcare reported Q2 2026 revenue of $673 million, up 2% year over year and 6% above the top end of guidance, with adjusted EPS of $0.77. Adjusted EBITDA was $73 million (10.9% margin) after $27 million in nonrecurring billing true-ups. Q3 revenue guidance is $640 million to $655 million. AMN also authorized share repurchases and acquired Jaide Health and ESSENTIAL.

AMN Healthcare Services reported Q2 revenue of $673.2 million, above analysts’ $628.2 million estimate, and adjusted EPS of $0.77 versus $0.19. Management attributed results to strong Nurse and Allied Solutions demand, including travel nurse and allied volumes, plus higher labor disruption revenue and improved search and international execution. Q3 revenue guidance midpoint was $647.5 million.

The article highlights three publicly traded stocks that, according to analyst expectations and reported results, beat or met second-quarter earnings. Allegiant Travel (ALGT) reportedly earned 15 cents vs a 3-cent estimate. IMAX (IMAX) reported 43 cents vs 30 cents. AMN Healthcare (AMN) met estimates at 44 cents per share.

AMN Healthcare Services’ shares rose about 17% to around $36 after Q2 results. Revenue was $673.2m vs $658.2m a year earlier. Adjusted EBITDA margin was 10.9%, aided by about $27m of nonrecurring items. The article notes Q3 guidance of $640m to $655m revenue and adjusted EBITDA margin of 6.5% to 7%.

Simply Wall St reports AMN Healthcare Services (AMN) swung from a loss to profit in Q2 2026 and posted higher sales, alongside updated Q3 revenue guidance. The stock fell 6.1% in one day and 11.26% over a week, though it is up 103.7% YTD. It cites fair value $31.86 vs $30.80 close and P/S 0.3x.

AMN Healthcare Services (NYSE: AMN) reported Q2 2026 revenue of $673 million, up 2% year over year, and adjusted EBITDA of $73 million. GAAP net income was $21 million, or $0.53/share, and adjusted EPS was $0.77. The company said results exceeded guidance, citing travel nurse and allied growth, 27% search revenue growth, and acquisitions expanding AI and leadership offerings. Q3 revenue is expected 1-3% higher.